BCM
ADVM

Bayesian Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Bayesian Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,756
Closed -$73.8K – 649
2024
Q2 		$73.8K Buy
+10,756
New +$100K 0.01% 661

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Bayesian Capital Management's ADVM Position: Q3 2024 in Review

Bayesian Capital Management sold out of Adverum Biotechnologies (ADVM) in Q3 2024, closing a stake of 10,756 shares — an estimated $73.8K sold.

Bayesian Capital Management first reported a position in ADVM in Q2 2024 and held it in 1 quarter. The position peaked at $73.8K in Q2 2024. 77 funds tracked by Wall St. Rank hold ADVM as of Q3 2024.

  • Bayesian Capital Management reported no remaining Adverum Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 10,756 Adverum Biotechnologies shares in Q3 2024, an estimated $73.8K.
  • Bayesian Capital Management first reported a position in Adverum Biotechnologies in Q2 2024 and held it in 1 quarter.
  • Bayesian Capital Management's Adverum Biotechnologies position peaked at $73.8K in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.